Table 2 Clinical and molecular characteristics of colon cancer patients according to MMR and CIMP 1
From: Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision
| Â | Â | Â | Molecular classifiers | |||
|---|---|---|---|---|---|---|
| Â | Â | Â | MMR system frequency N% | CIMP status frequency N% | ||
Clinical and pathological parameters | Â | Â | pMMR dMMR | p | CIMP-0 CIMP-L CIMP+ | p |
102 (85) 18 (15) | 62 (52) 36 (30) 22 (18) | |||||
Sex | Male | 50 (59) 7 (39) | 0.4 | 24 (39) 24 (67) 9 (41) | 0.02 | |
Female | 52 (41) 11(61) | 38 (61) 12 (33) 13 (59) | ||||
Tumour location | Proximal | 34 (33) 12 (67) | <0.01 | 25 (40) 9 (25) 12 (54) | 0.07 | |
Distal | 68 (67) 6 (33) | 37 (60) 27 (75) 10 (46) | ||||
Tumour grade | G1 | 13 (13) 3 (17) | <0.01 | 8 (13) 6 (17) 2 (9) | 0.04 | |
G2 | 88 (86) 12 (67) | 54 (87) 29 (81) 17 (77) | ||||
G3 | 1 (1) 3 (17) | 0 (0) 1 (2) 3 (14) | ||||
Tumour inflammatory response | No | 51 (50) 4 (22) | 0.03 | 26 (42) 20 (55) 9 (41) | 0.4 | |
Yes | 51 (50) 14 (78) | 36 (58) 16 (45) 13 (59) | ||||
Molecular parameters | TS by mRNA | High | 44 (43) 13 (72) | 0.02 | 22 (35) 19 (53) 16 (73) | <0.01 |
Low | 58 (57) 5 (28) | 40 (65) 17 (47) 6 (27) | ||||
TS by IHC | High | 52 (51) 6 (33) | 0.2 | 30 (48) 16 (44) 12 (55) | 0.2 | |
Low | 50 (49) 12 (67) | 32 (52) 20 (56) 10 (45) | ||||
TP53 | Positive | 44 (43) 2 (11) | <0.01 | 27 (44) 9 (25) 10 (45) | 0.1 | |
35 (56) 27 (75) 12 (55) | ||||||
Negative | 58 (57) 16 (89) | |||||
CTNNB1 activation grades | 1 | 34 (33) 11 (66) | 0.02 | 19 (31) 19 (53) 7 (32) | 0.08 | |
2 | 54 (53) 3 (17) | 33 (54) 15 (42) 9 (41) | ||||
3 | 14 (14) 3 (17) | 9 (15) 2 (5) 6 (27) | ||||
BRAF c.1799 T>A | Wild | 91 (89) 13 (72) | 0.05 | 54 (87) 32 (89) 18 (82) | 0.7 | |
| Â | Â | Mutated | 11 (11) 5 (28) | Â | 8 (13) 4 (11) 4 (18) | Â |